secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000950170-23-038002
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Q2 net loss $114M ($0.59/shr); cash $325.9M; SC291 enrollment ongoing, data expected H2 2023
--------------------------------------------------------------------------------

- Net loss of $114M in Q2 2023 vs $72.5M in Q2 2022; six-month net loss $196.1M.
- Cash, cash equivalents, and marketable securities $325.9M as of June 30, 2023, expected to fund operations into 2025.
- Enrolling patients in ARDENT Phase 1 trial for SC291 (CD19 CAR T) in B-cell malignancies; initial clinical data expected in H2 2023.
- Plan to file IND for SC262 and SG299 in hematologic cancers and SC451 (islet cell) in type 1 diabetes in 2024.
- Appointed Doug Williams as President of R&D and Gary Meininger as CMO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000095017023038002/0000950170-23-038002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000095017023038002/sana-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-038002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer